All In MedTech

Device Trial Radar · NCT02918942

Tympanoseal (Tympanic Membrane Device) Clinical Study

Last checked: Nov 20, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

25

Actual

Start

Oct 4, 2016

Primary completion

Sep 30, 2021

Study completion Sep 30, 2021

Sponsor

Lead sponsor
Grace Medical, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Sep 29, 2016

More device trials from this sponsor

Design

Study type
Interventional
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this investigational study is to assess the ability of Tympanoseal (sodium/calcium alginate), an investigational device, to act as a scaffold during healing of the tympanic membrane. Tympanoseal is intended for use following removal or extrusion of indwelling tympanostomy tubes or traumatic injury of the tympanic membrane.

Conditions

  • Tympanic Membrane Perforation

Interventions

  • TympanosealDevice

    All subjects will receive the Tympanoseal device that will be placed during a surgical procedure.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Serious Adverse EventsTime frame: 16 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UT Southwestern Medical Center

    Plano, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.